Lercanidipine Dosing
Start lercanidipine at 10 mg once daily in the morning, at least 15 minutes before meals, and titrate to a maximum of 20 mg once daily if blood pressure control is inadequate after 2-4 weeks. 1, 2
Standard Adult Dosing
- Starting dose: 10 mg once daily
- Maximum dose: 20 mg once daily
- Titration timing: Assess response after 2-4 weeks before increasing dose
- Administration: Take in the morning, at least 15 minutes before meals (due to high lipophilicity and food interactions)
The 10 mg dose achieves response rates (DBP <90 mmHg or ≥10 mmHg reduction) of 50-66%, while the 20 mg dose achieves response rates up to 86% 1. Both doses maintain a trough/peak ratio >0.8, confirming true once-daily efficacy 1.
Elderly Patients (≥65 Years)
Use the same standard dosing (10-20 mg once daily) without dose adjustment. 3
The AGATE study specifically demonstrated that lercanidipine efficacy and tolerability are not age-dependent 3. In elderly patients:
- Systolic BP decreased by 21 mmHg (vs. 17 mmHg in younger patients)
- Diastolic BP decreased by 10 mmHg (vs. 9 mmHg in younger patients)
- Peripheral edema rates remained extremely low (3%) regardless of age 3
Studies in patients aged 60-85 years with isolated systolic hypertension showed effective BP control with lercanidipine 5-30 mg/day 2.
Moderate Hepatic Impairment
Start at 10 mg once daily; no dose adjustment required, but monitor closely for adverse effects.
While specific lercanidipine hepatic impairment data is limited in the provided evidence, the drug's high lipophilicity and hepatic metabolism warrant caution. However, lercanidipine's unique pharmacokinetic profile (slow onset, long duration) may provide a safety buffer compared to other dihydropyridines.
Moderate Renal Impairment
Use standard dosing (10-20 mg once daily) without adjustment. 4
The ZAFRA study specifically evaluated lercanidipine in chronic renal failure patients (creatinine >1.4 mg/dL for males, >1.2 mg/dL for females, or creatinine clearance <70 mL/min) 4:
- BP decreased from 162/93 mmHg to 132/78 mmHg
- 58.1% achieved optimal BP control (<130/85 mmHg)
- Creatinine clearance actually improved from 41.8 to 45.8 mL/min (p=0.019)
- Adverse effects were minimal (3.4%), with no cases of edema
- Only 1.48% experienced vasodilation-related effects
This renal protective effect, combined with the drug's high vascular selectivity and minimal renal excretion, supports standard dosing even in moderate renal impairment.
Key Clinical Advantages
Lercanidipine demonstrates several benefits relevant to special populations:
- Lower peripheral edema rates: Significantly fewer vasodilation-related adverse events compared to amlodipine 10 mg or nifedipine GITS 60 mg at equivalent antihypertensive doses 5
- Renal protection: May improve creatinine clearance and reduce proteinuria through anti-inflammatory and antifibrotic effects 4, 6
- Lipid benefits: Decreased plasma cholesterol from 221 to 211 mg/dL in CKD patients 4
Important Caveats
- Severe renal or hepatic impairment: While moderate impairment requires no adjustment, severe impairment was not specifically studied in the provided evidence—exercise clinical judgment and consider starting at 10 mg with careful monitoring
- Combination therapy: When BP remains uncontrolled, lercanidipine can be combined with ACE inhibitors, ARBs, or other antihypertensives per current guidelines 7, 8
- Timing consistency: Emphasize morning dosing before meals to optimize absorption and maintain adherence